GW’s lead product, Sativex^®, is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development.

Sativex® is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a condition that previously had limited treatment options.

GW is recognised as a world leader in cannabinoid science and works closely with a global network of clinicians and scientific collaborators at 25 academic institutions across the world.

GW is also researching medicines based upon its validated cannabinoid platform to treat a range of other conditions including pain, cancer, diabetes, and epilepsy.

With a commercial product, valuable pipeline, prestigious pharmaceutical partners, diversified business model, and a highly capable in-house team, GW is well placed for growth and value creation.